Table 3.

Summary of the key parameters used in this study. The molecular weight (MW) has a unit of Da. The extinction coefficient (EC) has a unit of ml/mg/cm. The net charge is based on the antibody’s full-length sequence and molecular structure (using Propka) and has a unit of e. SCM represents the spatial charge map score. HVI represents the high viscosity index

mAbs	pI	MW	EC	net charge	SCM	HVI
Ganitumab IgG1	8.75	145455.4	1.606	38	806.5	15.15
Ganitumab IgG4P	7.58	145144.7	1.609	24	759.9	15.15
Adalimumab IgG1	8.72	145190.9	1.463	32	1316.6	16.67
Adalimumab IgG4P	7.55	144880.3	1.466	18	1325	16.67
Cetuximab IgG1	8.54	145188.7	1.498	26	1127.9	20.35
Cetuximab IgG4P	7.25	144878	1.501	12	1046.3	20.35
Tremelimumab IgG1	8.93	146572.4	1.551	34	704.2	18.97
Tremelimumab IgG4P	8.23	146261.8	1.554	20	723.6	18.97
Ipilimumab IgG1	8.46	144911.7	1.57	36	754	15.49
Ipilimumab IgG4P	8.34	144768.2	1.544	22	769.2	15.49
Basiliximab IgG1	9.12	143522.9	1.619	40	640.8	25.11
Basiliximab IgG4P	8.72	143212.2	1.623	26	637.1	25.11
Natalizumab IgG1	8.68	146344.3	1.533	28	815.5	20.52
Natalizumab IgG4P	7.55	146033.7	1.536	16	809.3	20.52
Vesencumab IgG1	8.97	144910.7	1.411	34	661.3	14.78
Vesencumab IgG4P	8.25	144600.1	1.414	20	693	14.78
Atezolizumab IgG1	8.53	144377.9	1.624	30	759.6	13.33
Atezolizumab IgG4P	7.28	144067.3	1.627	16	774.3	13.33
Trastuzumab IgG1	8.41	150000	1.43	34	700.2	17.18
Trastuzumab IgG4P	7.91	144792.2	1.488	20	690.6	17.18
TGN1412 IgG1	8.79	145689.5	1.554	38	844.6	21.15
TGN1412 IgG4P	7.91	145378.8	1.558	24	808.3	21.15
Bevacizumab IgG1	8.25	146243.8	1.664	30	987.3	19.1
Bevacizumab IgG4P	7.05	145933.2	1.668	16	997	19.1
Omalizumab IgG1	7.36	146215.4	1.569	26	1193.7	21.6
Omalizumab IgG4P	6.63	145904.7	1.572	12	1086.8	21.6
Golimumab IgG1	8.98	146688.6	1.489	36	807.2	13.2
Golimumab IgG4P	8.32	146378	1.492	22	785.2	13.2